Important addition to Eaton VANCE WORLDWIDE HEALTH SCIENCES FUND

Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) has recently submitted an N-port application in the fourth quarter of 2024 and has revealed strategic investment decisions. Boston and London, which is based in Boston and London, focuses on companies engaged in healthcare progress, such as biotechnology, pharmaceuticals, and medical equipment. Funds aim to increase medical expenses, focusing on growth due to population statistics, innovation, and global income. Portfolio managers prioritize shares that are reasonably priced compared to basic values ​​that have the potential for long -term growth. This approach includes factors such as the possibility of market share of large companies and the outlook for small entities' research and development.

Eaton Vance Worldwide Health Science Fund (Trades, Portfolio) has been added in total.

The most important additions are 273,749 shares, a NYSE (NYSE: ABT), a 3.23 % portfolio, a total of $ 32,513,170 million.

The second largest addition to the portfolio is Gilead Science Inc (NASDAQ), which consists of 225,867 shares, accounting for about 2.08 % of the portfolio, a total of $ 20,910,770.

The third largest addition is the Edwards LifeSciencies Corp (NYSE), 149,979 shares of 149,979, accounting for 1.06 % of portfolios and a total of $ 10,701,000.

Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) has also increased a total of eight shares.

The most notable increase was Bristol Meyers Squive (NYSE: BMY), an additional 108,314 shares, a total of 601,243 shares. This adjustment indicates a significant increase of 21.97 % of the share count, which has a 0.64 % impact on the current portfolio, with a total value of $ 35,605,610.

The second largest increase was Straumann Holding AG (XSWX: STMN), which brought a total of 71,699 for 22,825 strains. This adjustment indicates a significant increase in the share count of 46.7 %, the total of 9,369,990.

Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) has completely finished three possessions in the fourth quarter of 2024.

Humana Inc (NYSE: HUM): The fund sold all 55,766 shares and affected the portfolio of -1.78 %.

PFIZER Inc (NYSE: PFE): The fund liquidated all 359,209 shares and influenced the portfolio of -0.94 %.

The story will continue

Eaton VANCE WORLDWIDE HEALTH SCIENCES FUND (Trades, Portfolio) has also reduced 15 shares. The most important changes are:

STRYKER CORP (NYSE) decreased by 39,569 shares, shares decreased -57.11 %, which has a -1.28 % impact on portfolios. The shares were traded at $ 367.2 in the quarter, returning 12.57 % in the last three months and 10.06 % a year.

SANOFI SA (XPAR: SAN) decreased by 104,190, as a result of -31.74 % of shares, and the portfolio was -1.05 %. The shares were traded at a average price of 99.32 during the quarter, returned 2.62 % in the last three months and 6.85 % from the beginning of the year.

In the fourth quarter of 2024, the portfolio of Eaton Vance Worldwide Health Science (Trades, Portfolio) contained 46 stocks. Top Holdings includes 9.37 % of Eli Lilly and Co (NYSE: LLY), 8.71 % for UnitedHealth Group Inc (NYSE: Unh), NOVO NORDISK AS (NOVO NORDISK AS (OCSE: Novob B), 5.42 % for ABBVIE INC (NYSE) and 4.12 % for intuitive surgery Inc (NASDAQ: ISRG).

Publishing is mainly concentrated on healthcare, one of the 11 industries.

This article generated by GuruFocus is designed to provide general insights and is not a adjusted financial advice. Our commentary is rooted in history data and analysts that use fair methodology and do not intend to function as a specific investment guidance. It does not formulate recommendations for purchasing or selling shares, and does not consider individual investment targets or financial situations. Our purpose is to provide long -term basic data -driven analysis. Note that our analysis does not incorporate the announcement of a company that is sensitive to the latest prices or qualitative information. Gurfocus does not hold the position in the stock described here.

This article was first published in Gurufocus.